QOL of Multiple Myeloma Patients Receiving Maintenance Therapy

Video

This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.

In this interview, Rafat Abonour, MD, of the Indiana University Simon Cancer Center, discusses a study that examined the health-related quality of life of multiple myeloma patients who received maintenance therapy in a real-world setting.

Patients in the study (abstract 537) were part of the Connect MM registry. Patients had newly diagnosed disease, and the researchers compared those who received maintenance therapy (a majority with lenalidomide) after autologous stem cell transplant with those who did not.

Dr. Abonour presented results of the trial at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3–6 in San Diego, California.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.